News Archive

February 2020

• 
  StoryFeb 25, 2020 People and Culture

  Parental Leave at Novartis: Alfred’s story

  At Novartis, we celebrate life and recognize moments that matter. Alfred Ambatlle shares his experience of parental leave and becoming a father of twins.

• Media ReleaseFeb 25, 2020

  Novartis and DNDi to collaborate on the development of a new oral drug to treat visceral leishmaniasis

  LXE408 is a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust Novartis is responsible for completing Phase I clinical trials and has committed to…
• 
  StoryFeb 24, 2020 Discovery

  Shaping the future of sickle cell disease

  Collaborations are driving advances in sickle cell disease research, bringing new hope to patients.

• Media ReleaseFeb 24, 2020

  Novartis announces FDA and EMA filing acceptance of ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS)

  Filings are supported by Phase III ASCLEPIOS I and II studies, where ofatumumab showed highly significant and clinically meaningful reduction in the number of confirmed relapses, evaluated as…
• 
  StoryFeb 18, 2020 Access to Healthcare

  Collaboration is strengthening care for chronic illness in Ethiopia

  Working with a nonprofit, Novartis is helping train healthcare workers to diagnose and treat chronic ailments such as diabetes.

• Media ReleaseFeb 17, 2020

  Novartis receives EC Approval for Beovu®, a next-generation anti-VEGF treatment for wet AMD, a leading cause of blindness worldwide

  Beovu (brolucizumab) is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on three-month dosing intervals immediately after the loading…
• Media ReleaseFeb 11, 2020

  Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review

  FDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping (METex14) mutated advanced non-small cell lung cancer (NSCLC)1 …
• StatementFeb 05, 2020

  AVXS-101 Managed Access Program
• Featured NewsFeb 04, 2020

  World Cancer Day 2020

  Novartis is supporting World Cancer Day by reimagining cancer in the workplace through a dedicated global program.

• 
  StoryFeb 04, 2020 People and Culture

  Reimagining cancer in the workplace

  Novartis is strongly committed in helping and supporting employees impacted by cancer through the program Ensemble – Caring for Colleagues (Ensemble).

• In The NewsFeb 03, 2020

  Novartis CEO Vasant Narasimhan on building trust with society

  Vas Narasimhan, CEO of Novartis, and CNBC’s Meg Tirrell joins “Closing Bell” in an exclusive interview at the JPMorgan Healthcare Conference.
• In The NewsFeb 03, 2020

  Novartis Pharmaceuticals head on chief, Marie-France Tschudin on rethinking the drug-launch formula

  Tschudin talks with FiercePharma at the J.P. Morgan Healthcare Conference.about a “value-based approach” to drug launches.